Therapeutic Plasma Exchange in Acute Liver Failure: can the data be trusted? [0.03%]
急性肝衰竭血浆置换疗法的数据可信吗？
Alaa Daoud,Kim Peder Dalhoff,Tonny Studsgaard Petersen
Alaa Daoud
Reply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFNα based therapy" [0.03%]
高雪等文章的作者回复
Rex Wan-Hin Hui,Lung-Yi Mak,Man-Fung Yuen
Rex Wan-Hin Hui
Roux-en-Y gastric bypass in a patient with Wilson's disease and obesity [0.03%]
一位患有威尔森病和肥胖症患者的 Roux-en-Y胃旁路手术案例报告
Alexandre Balaphas,Christine Sempoux,Caroline F Samer et al.
Alexandre Balaphas et al.
Thomas Marjot
Thomas Marjot
Introducing the Updates in Clinical Science: A focus on recent data of high impact [0.03%]
临床科学更新介绍——聚焦高影响力的新数据
Vlad Ratziu,Tom H Karlsen
Vlad Ratziu
RORc expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions [0.03%]
RORc表达的免疫细胞负向调控三级淋巴样结构的形成并维持其促肿瘤功能
Einat Cinnamon,Ilan Stein,Elvira Zino et al.
Einat Cinnamon et al.
Background and aims: RORc-expressing immune cells play important roles in inflammation, autoimmune disease and cancer. They are required for lymphoid organogenesis and have been implicated in tertiary lymphoid structure (...
AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B [0.03%]
基于CT影像标志物的人工智能模型预测慢性乙型肝炎患者肝细胞癌风险的研究
Hyunjae Shin,Moon Haeng Hur,Byeong Geun Song et al.
Hyunjae Shin et al.
Background & aims: Various hepatocellular carcinoma (HCC) prediction models have been proposed for patients with chronic hepatitis B (CHB) using clinical variables. We aimed to develop an artificial intelligence (AI)-base...
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies [0.03%]
酒精性与非酒精性肝细胞癌的差异
Nathalie Ganne-Carrié,Pierre Nahon
Nathalie Ganne-Carrié
Alcohol-related liver disease is the third cause of hepatocellular carcinoma worldwide and the leading cause in Europe. Additionally, the recent definition of Metabolic dysfunction-Associated Steatotic Liver Disease with increased alcoholic...
Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma [0.03%]
单细胞RNA测序衍生标志物定义了晚期肝细胞癌接受阿特朱单抗+贝伐珠单抗治疗的反应模式
Sarah Cappuyns,Marta Piqué-Gili,Roger Esteban-Fabró et al.
Sarah Cappuyns et al.
Background & aims: The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we...
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study [0.03%]
HEC88473治疗MASLD和T2DM的疗效与安全性：一项随机、双盲、安慰剂对照研究
Lin Xiang,Guixia Wang,Yulei Zhuang et al.
Lin Xiang et al.
Background and aims: Glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) are key regulators of glucose and lipid metabolism. In the present study, we assessed the safety and efficacy of a novel GLP-1/F...